Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 22nd Annual Healthcare Conference
WALTHAM, Mass., Dec. 6, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the Oppenheimer 22 nd Annual Healthcare Conference at 3:55 pm ET on December 13, 2011 will be
View HTML
Toggle Summary ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly
Agreement provides Lilly, a leader in the development of important cancer therapeutics, with access to ImmunoGen's TAP technology ImmunoGen to receive $20 million upfront, milestone payments potentially totaling $200 million — for each target — and royalties on any commercial sales WALTHAM, Mass.,
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the J.P. Morgan 30th Annual Healthcare Conference
WALTHAM, Mass., Jan. 3, 2012 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the J.P. Morgan 30 th Annual Healthcare Conference at 2:00 pm PT on January 10, 2012 will be
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2012 Financial Results
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2012 Financial Results WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 18, 2012-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the
View HTML
Toggle Summary ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
Product pipeline progress includes continued advancement of trastuzumab emtansine (T-DM1) toward Phase III data reporting and marketing submission in 2012, initiation of SAR3419 multi-study Phase II program; and progression of IMGN901 toward Phase II start.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors
WALTHAM, Mass., Jan. 30, 2012 (GLOBE NEWSWIRE) -- ImmunoGen, Inc . (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody expertise, today announced the addition of Kristine Peterson and Dean Mitchell to the Company's Board of Directors.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: 14 th Annual BIO CEO &
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen 32nd Annual Health Care Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the Cowen 32 nd Annual Health Care Conference at 10:40 am ET on March 7, 2012 will be webcast live.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial
Roche has announced lead Phase III trial with trastuzumab emtansine has met progression-free survival endpoint Plans to apply for marketing approval of trastuzumab emtansine in US and Europe Study data being submitted for presentation at major medical meeting WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate
NORTH trial assesses impact of adding IMGN901 to standard care for first-line treatment of small-cell lung cancer (SCLC). Trial includes planned interim analysis to enable early decisions on next steps to advancement. WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc.
View HTML